ABSTRACT -A cloned subline of the human monocytic leukemia cell line, THP-1, was induced to produce high levels of cytotoxic activity following an 18-hour phorbol myristate acetate (CAS: 16561-29-8) stimulation in vitro. This activity, termed monocyte cell line cytotoxin(s) (MCCT), was tested in vitro on different human continuous cell lines (Chang, ESH-7, GM3104A, HeLa, HT-1080, K562, Mel, T-24) and on primary human fibroblasts (GM3468, Manz). The continuous cell lines exhibited a spectrum of sensitivity to MCCT-containing supernatants whereas the primary fibroblasts were resistant to lysis. Enzymatic degradation and heat denaturation studies indicate that MCCT is a protein. Its bioactivity can be resolved into three lytic peaks after molecular sieving on Ultrogel AcA 44. The major peak, designated aMCCT, eluted with a molecular weight of 100,000-140,000 daltons. A minor peak, {3MCCT, was seen at 60,000-80,000 daltons, and a third, unstable minor peak,,,MCCT, eluted at less than 10,000 daltons. The a-lytic peak was examined further and was found to migrate as a single peak in 7% native polyacrylamide gel electrolysis tube gels with an r, of 0.25-0.30. None of the MCCT forms were immunologically cross-reactive with human a-Iymphotoxin. Various protease inhibitors known to inhibit monokine-and macrophage-mediated direct cell lysis in vitro were tested for their inhibitory effects on aMCCT activity. The irreversible binding inhibitor Na-p-tosyl-L-Iysyl chloromethyl ketone inhibited the biologic activity of aMCCT. The reversible binding inhibitors Na-p-tosyl-L-arginine methyl ester and soybean trypsin inhibitor were able to block in vitro lytic activity when added to aMCCT in the presence of the target cell. In contrast, the inhibitors phenylmethylsulfonyl fluoride, L-1-tosylamide, 2-phenylethyl chloromethyl ketone, and Na-acetyl-L-Iysine methyl ester were not effective in blocking cytolysis. Finally, the hydrogen peroxide scavenger catalase inhibited aMCCT lytic activity in vitro; however, the hypochlorous acid scavengers alanine, serine, and valine were without effect. -JNCI 1985; 74:1-9. Human peripheral blood monocytes and alveolar macrophages can be raised to a cell-lytic state by treatment in vitro with lymphokines and/or bacterial components (1-5). These activated human mononuclear cells exhibit a greater capacity to lyse neoplastic cells rather than primary cells in vitro. In addition, recent reports have demonstrated the release of eLM from peripheral blood monocyte and alveolar macrophage cultures [(6-8); Klostergaard J: In preparation; Sone S, Lopez-Dertein G, Fidler IJ: In preparation). Supernatants containing eLM from these cultures were also found in general to preferentially lyse continuous cells over primary cells in vitro.
Human peripheral blood monocytes and alveolar macrophages can be raised to a cell-lytic state by treatment in vitro with lymphokines and/or bacterial components (1) (2) (3) (4) (5) . These activated human mononuclear cells exhibit a greater capacity to lyse neoplastic cells rather than primary cells in vitro. In addition, recent reports have demonstrated the release of eLM from peripheral blood monocyte and alveolar macrophage cultures [(6-8) ; Klostergaard J: In preparation; Sone S, Lopez-Dertein G, Fidler IJ: In preparation). Supernatants containing eLM from these cultures were also found in general to preferentially lyse continuous cells over primary cells in vitro.
For the in-depth investigation of eLM, the production of large amounts of human supernatant would be necessary from a homogeneous monocyte-macrophage source, preferably from a single donor. Primary cultures 1 of monocytes from many individual donors do not fulfill these criteria. To circumvent these problems, attention has been focused on recently derived human cell lines of monocytic and histocytic origin as possible sources of these cytolytic monokines. The U937 line has proven to be a valuable model for several aspects of human monocytes-macrophages after lymphokine activation (9) (10) (11) . Other cell lines appear to be arrested at a very early stage in monocyte-macrophage differentiation and attempts to activate them with lymphokines or LPS have not resulted in release of eLM (12) (13) (14) . However, two well-characterized human monocytic cell lines in the pr~sence of PMA will differentiate in vitro into cells that express many of the functional characteristics of mature macrophages. Specifically, the HL-60 (12) and THP-I-O (14) cell lines have been shown to stop cell division, become glass adherent, increase phagocytosis, and express increased cell surface esterase staining. In addition, the HL-60 cell line becomes lytically active after incubation with PMA (15, 16) .
In the present study, we describe the isolation of a clone of the THP-I cell line termed A Y -23, which, upon PMA stimulation in vitro, releases high levels of eLM activity. This activity, termed MeeT, exhibits the functi'onal ability to lyse continuous cells and not primary 2 Armstrong, Klostergaard, and Granger fibroblasts in vitro. The biologic activity of MCCT can be attributed to distinct proteins that can be obtained in sufficient quantity for purification and for future functional and biochemical studies.
MATERIALS AND METHODS
Culture media and cell lines.-Culture media used in these studies consisted of RPMI-1640 medium (GIBCO, Grand Island, NY) supplemented with RPMI-3% or RPMI-IO% (GIBCO), 100 J..Lg streptomycin/ml (Sigma Chemical Co., St. Louis, MO), and 100 U penicillin/ml (Sigma Chemical Co.).
Target cells were grown in 16-ounce prescription bottles in either RPMI-3% for murine cells or in RPMI-10% for human cells at 37°C in 5% C02 and passed biweekly. The adherent continuous lines used were L-929 cells, referred to as L-cells (17) ; HeLa, human cervical carcinoma; HT -1080, human skin fibrosarcoma; Chang, human liver carcinoma; T -24, human bladder carcinoma; \. ESH-7, a cell line derived from the fusion between HeLa . cells and WIL-2, a human B-cell lymphoma; and Mel, human melanoma. The adherent human primary cell strains used were GM3468, primary fetal foreskin fibroblasts, and Mauz, primary skin fibroblasts. The primary strains were passed at confluence and were replenished from frozen (-80°C) stock after 30 passages. Nonadherent human target cells were also employed; they were, GM3104A, a human B-cell lymphoma, and K562, a human erythroblastoma. These lines were maintained in RPMI-IO% at 37°C in 5% CO 2 atmosphere and passed biweekly.
Human monocytic cell line.-The human monocyte leukemia cell line THP-l (13), a gift from Dr. Jun Minowada, New York State Department of Health, Buffalo, NY, was used as the source of cell-lytic materials in these studies. This cell line was cultured in RPMI-I 0% in Corning T-75 cm 2 flask (Corning, NY) in an atmosphere of 5% C02 at 37°C and subcultured every third day at an initial density of 3X 10 4 cells/ml. A done of this cell line was isolated by the limiting dilution method in the presence of a feeder layer of 2X 10 4 BALB/ c peritoneal macrophages per microtiter well in 96 flat-bottomed well microtiter plates in RPMI-IO% (Flow Laboratories, Inglewood, CA). After 3 weeks in culture, several wells from the limiting dilution step contained single colonies of cells. These colonies were selected and the cells recloned in 96-well microtiter plates by the limiting dilution technique in preconditioned media from BALB/c peritoneal macrophage cultures. After 3 weeks in culture, colonies of cells appeared. These dones were then transferred into I-ml cultures in Costar 24-well plates containing 50% preconditioned media and 50% fresh RPMI-IO%. These clones were subsequently expanded in RPMI-IO% and tested for production of cytolytic material.
Production of cytolytic material from THP-l and clones.-THP-l cells and clones were grown to a cell density of 5X10 5 cells/ml in RPMI-IO%. These cultures were then pelleted by centrifugation at 450Xg for 8 minutes and 5X 10 5 cells/ml were resuspended in 40 ml of JNCI. VOL. 74, NO. I. JANUARY 1985 fresh RPMI-lO% in 32-ounce prescription bottles in a 5% CO 2 atmosphere. Varying amounts of PMA (Sigma Chemical Co.) at an initial concentration of 50 J..Lg/ml dissolved in 95% ethanol were then added to the cultures. After incubation at 37°C for various time intervals, the PMA-containing media were discarded and the now adherent monolayer was washed three times with RPMI-0% to remove any residual PMA. At this point, 40-50 ml of RPMI-LAH (GIBCO), which served as a serum substitute, was added to the culture. After incubation for an additional 2-72 hours at 37°C, supernatants were collected, and cell debris was removed by centrifugation at 500Xg for 10 minutes, filter sterilized, then used immediately or stored at -70°C. Concentration of supernatants or partially purified fractions was achieved by ultrafiltration in an Amicon 8200 Stirred Cell (Amicon Corp., Danvers, MA) with the use of a 62-mm PM-10 Diano ultrafiltration membrane (Amicon Corp.).
Cytolytic cell assays.-Two types of assays were employed: One determined quantitatively the amount of cytolytic activity present in a given supernatant, and the other indicated only the presence or absence of activity in the supernatant as percent lysis. a) Tube assay: The details of this method have been reported previously (17) . Briefly, I X 105 mitomycin target cells in 1.0 ml were established as nondividing monolayers in l6X125-mm culture tubes. Either serial dilutions of the test or control medium (quantitative assay) or a single aliquot of a sample (qualitative assay) was added to duplicate tubes. After an additional 24-hour incubation at 37°C, the remaining adherent cells were trypsinized and enumerated in a Model F Coulter Counter (Coulter Electronics, Hialeah, FL). Units of cell-lytic activity per milliliter of a given supernatant were obtained by determining the reciprocal of the dilution killing 50% of the target cells.
b) Microplate assay: Mitomycin-treated cells at a density of I X 10 4 cells/lOO J..Ll were dispensed into flatbottomed 96-well microtiter plates (Corning) and incubated at 37°C in a humidified air and 5% CO 2 -containing incubator. After 24 hours, serial dilutions of MCCTcontaining supernatants or fractions and control media were added to triplicate wells. After an additional 24 hours of incubation, the media were aspirated and the remaining viable adherent targets fixed to the substrate and stained with a 1:1,000 crystal violet solution (18) . We found, by eosin Y -dye exclusion from a non treated or control well, that 90% of the detached targets were nonviable, as reported previously (19) . Suspension targets were removed from the wells by aspiration and stained with 0.1% eosin Y-dye as described previously (19) , and the viable and nonviable cells enumerated in a hemacytometer. The percent cytolysis in these cultures was viable cells in control well)] X 100, where the average percent was determined by the mean of triplicate wells. L-cells were used only in tube assays; HeLa cells were used in both tube assays and in microplate assays, as indicated. All other target cells were used only in microplate assays.
Antiserum neutralization assays.-Production, characterization, and testing of rabbit antisera that neutralize L T forms in vitro have been previously reported (20) . All antisera were heat inactivated for I hour and centrifuged at 20,000Xg for 30 minutes before use. Neutralization of MCCT activity was performed by adding 2S-S0 IJI of antiserum or NRS to 10 U of MCCT activity from a supernatant or fraction, preincubation for 30 minutes at 2SoC, then testing the remaining activity on L-cells. The percent neutralization of MCCT activity was determined by the following formula: Percent neutralization = Discontinuous PAGE.-A ISO-1J1 sample of MCCT in 20% sucrose and 0.001 % bromphenol blue was applied to a 0.SX8-cm gel column consisting of a I-cm 3% acrylamidestacking gel in SO mM Tris-glycine, pH 9.0, and a 7-cm 7% acrylamide separation gel according to the method of Davis (21) . The gels were then cut in I-mm slices, and cytolytic material was eluted by incubation for 10-12 hours in 2S0 IJ} RPMI-3% at 4°C. A 100-to 200-IJI sample was then tested for cytolytic activity.
Protease inhibitors.-Pooled molecular sieving fractions containing active aMCCT buffered with a potassium phosphate (100 mM P0 4 , pH 7.2) buffer were employed in these studies. The methods employed for protease inhibitor treatment have been described previously (29) . The irreversible binding inhibitors used were TLCK, TPCK, and PMSF, all from Sigma Chemical Co. A l.S-ml sample containing approximately 10-20 U of aMCCT Iml was reacted for ! hour at 37°C with varying concentrations (0.4-10 mM) of the different inhibitors. The sample was then dialyzed against approximately 1,000 volumes of PBS for 10-12 hours at 4°C. After dialysis, the lytic activity of each sample was determined. Samples with aMCCT activity were also incubated for I hour at 37°C without inhibitor, dialyzed against SOO volumes of PBS for 10-12 hours, and assayed for toxicity. As a control, 10 mM TLCK, I mM PMSF, or 1 mM TPCK was added to RPMI-LAH, incubated for 1 hour, dialyzed against PBS overnight, and assayed for toxicity.
The reversible inhibitors TAME (Sigma Chemical Co.) and ALME (Sigma Chemical Co.) were added with 10-20 U of aMCCT directly to the target cells. After 20 hours, the level of lysis in these cultures was compared to levels of aMCCT-induced lysis in the absence of inhibitor. Extensive testing revealed that neither drug was toxic to the target cells at levels up to 10 mM. SBTI (grade 4.; Sigma Chemical Co.) at 0.1 and 1.0 mM was incubated directly with 10-20 U of MCCT for 30 minutes at room temperature. The samples were then assayed directly on target cells. As a control, the same amount of SBTI in 100 mM phosphate buffer was added directly to target cells. The percent inhibition of lysis in all studies was determined by the following formula: Percent lysis =
Inhibitors of active oxygen radicals.-Catalase (33,900 U 1m!, beef liver extract; Sigma Chemical Co.) at a known level of enzymatic units per milliliter was added to L-cell assays simultaneously with aMCCT or with control supernatants containing no MCCT. The percent inhibitioh of aMCCT activity by catalase was determined with the same formula used with the protease inhibitors described above.
The amino acids alanine, serine, and valine (Sigma Chemical Co.) were dissolved in PBS, pH 7.2. These solutions were added simultaneously with aMCCT from molecular sieving to L-cell assays, and the percent inhibition was calculated. The final concentration of added amino acid was 30 ruM.
RESULTS
Release of eLM in vitro.-THP-Icells grown to a density of SX 105 cells/ml were exposed to a lymphokinerich supernatant from 3-day cultures of phytohemagglutinin-stimulated human tonsil and adenoid lymphocytes (23) with a procedure similar to that used by Fisher et al. (4) to produce cytotoxin(s) from human peripheral blood monocytes in vitro. This supernatant was added to THP-I-O cell cultures at ratios of I:S or 1:10 (vol/vol). After 24 hours, SOO ng LPS/ml was added directly to the cultures for either I or 2 hours, the LPS was removed by washing the cells in serum-free media, and the cells were resuspended in fresh RPMI-lO% for an additional 24 hours. Samples from both the lymphokine-enriched supernatant without LPS and the supernatant obtained 24 hours after LPS removal were collected and assayed on L-cells for cytotoxicity. No cytolytic activity was detected in either of these supernatants.
THP-I cells were reported to differentiate into cells expressing the characteristics of mature macrophages after exposure to PMA in vitro (14) . When cultures of 2X10 5 THP-I cells/ml were exposed to 10 ng PMA/ml, the cells were observed to become glass adherent after 3 hours while maintaining high (>90%) viability as determined by eosin Y -dye exclusion. However, 24-hour supernatants from these cultures were not cytotoxic. We subsequently tested various levels of PMA .and found that supernatants from THP-l cultures after exposure to 100 ng PMA/ml for 24 hours exhibited cytotoxic effects when tested on L-cells. In contrast, no toxicity was detected when 100 ng PMA/ml was added to either RPMI-IO% or RPMI-O% and these media were assayed on L-cells. The results shown in table 1 summarize these initial data. It is obvious that cytotoxic activity was found in the supernatants only after PMA was added to the THP-l cultures.
Kinetics of cytotoxin release.-Cell density, dosage of PMA, and incubation times necessary to achieve maximum MCCT release were examined. We first tested various cell numbers and found that a density of 5X 105 cellslml gave the optimal levels of MCCT production; this cell density was used throughout further experiments. Subsequently, we incubated the cells in RPMI-10% with various concentrations of PMA for the indicated time periods. The levels of MCCT were quantified on L-cells; data from these studies are presented in table 2. The lowest concentration of PMA that induced MCCT release was 50 ng/ml. At this and higher levels of PMA, lytic activity appeared between 18 and 24 hours and increased to greater than 1,000 Ulml after 48 hours. To facilitate biochemical studies, it was important to es-). tablish if MCCT would be released into a serum-free medium. Cells were incubated with PMA for 18 hours in RPMI-1O% as described above; then the cultures were transferred into. RPMI-LAH without PMA. Under these conditions LAH serves as a serum substitute. Supernatants from these cultures were assayed for levels of MCCT activity at various intervals. The results are presented in table 3. The data show that MCCT activity plateaus at 48 hours after removal of PMA. Also, 100 ng PMA/ml induced higher levels of MCCT release than 50 ng/ml. In all following experiments, 100 ng PMA/ml was used to stimulate the cells for 18 hours followed by a 48-hour release period. aOne unit of cell-lytic activity is the reciprocal of the dilution of MeeT that produces 50% lysis of lX10 5 L-cells in a I-ml culture.
b Control media assayed directly on L-929 cells. cZero units of activity indicates no detectable cytolytic activity. dLymphokine-rich medium was prepared from PHA-stimulated human tonsil and adenoid cultures as explained in "Results." THP-l cultures were treated with lymphokine-rich medium according to the method of Fischer et al. (4 0  0  NT  NT  0  0  NT  10  <5  <5  <5  <5  23  <5  50  <5  <5  <5  6  858  >1,000  75  <5  <5  <5  6  614  >1,000  100  <5  <5  <5  10  778  >1,000  200  <5  <5  <5  10  668  >1,000 a 5XI0 5 THP-l cells/ml stimulated with PMA for various intervals and supernatants collected. The number of cytolytic U/ml were then determined as described in "Materials and Methods." NT=not tested.
bOne unit is the reciprocal of the dilution of MCCT that produces 50% lysis of lX10 aTHP-l cells or clones at 5xI0' cells/ml were stimulated with PMA for 18 hr, washed three times, and allowed to release MCCT in RPMI-LAH for 48 hr.
bUnits of activity were determined as described in footnote b, table 2.
CData are mean values from 3 experiments ± standard error.
100-300 V/ml of MCCT activity were generated, collected, concentrated twentyfold to thirtyfold, filter sterilized, and supplemented with 10% fetal calf serum. The concentrates were then simultaneously tested on L-cells to determine the number of units of bioactivity per milliliter and assayed in triplicates on different target cell types previously treated with mitomycin. The percent lysis of the continuous and primary adherent targets was determined in the !picrotiter assay employing 10,000 cells/well. Additional studies revealed that more than 90% of detached cells were nonviable judged by staining with 0.1% eosin Y-dye. Lysis of the suspension target cells K562 and G M31 04A was determined as explained in "Materials and Methods." Table 5 lists the various targe(s tested, the tissue from which they were isolated, and the amount of MCCT (expressed in L-cell units) necessary to produce 50% lysis. These data are the mean of four separate experiments and values in parentheses give the range of variation between experiments. The data suggest that different cells exhibit a spectrum of sensitivity to MCCT. Clearly, the He La cell is the most sensitive. Cells expressing He La cell surface markers (Chang, ESH-7) were also sensitive but to a lesser degree. Of the continuous lines tested, the GM3104A and K562 cells showed no lysis. In none of the tests did the primary fibroblast strains (GM3468, Manz) show any lysis as measured by detachment, changes in shape, or viability staining with eosin Y-dye.
Antibody neutralization.
-MCCT activity was also tested to determine if it could be neutralized by rabbIt antisera made against L T. The anti-LT used were of two types: a) anti-WS, a polyspecific antiserum known to block the effects of most L T forms and b) anti-a2 made against highly purified a2-LT from phytohemagglutinin-stimulated human tonsils and adenoids (20, 23) . Neither of these antisera significantly neutralized (>20%) MCCT activity.
Determination of molecular weight of MCCT.-The supernatant from AY -23 cells was collected, concentrated twentyfold, and chromatographed on Vltrogel AcA 44 molecular sieving columns. Samples from each fraction were assayed on L-cells for cytolytic activity. Molecular weight markers employed were: BD > 200,000, IgG 150,000, Hb 64,000, a-Ct 23,000, and PR 364 daltons. As the data in text-figure I indicate, the major peak of lytic activity eluted within a molecular weight range of 100,000-140,000 daltons and was designated as the aform. A second lytic peak, termed l3-form, chroma tographed with an approximate molecular weight of 60,000-80,000 daltons. A third peak of activity, termed l'-form, was occasionally detected just in front of PRo We found that the l'-peak was unstable and lost all activity within 48 hours after sieving.
Fractions were also assayed on HeLa cells in tube cultures. Text-figure 2 shows a representative elution profile with this target cell. As with the elution profile on the L-cell, both the a-and l3-sizes of MCCT activity were detected; however, no l'MCCT activity was observed.
aMCCT from molecular sieving in a low-salt phosphate buffer (20 mM P042-, pH 7.2) was stable for up to 2 weeks at 4°C. The addition of 0.05% LAH to the fractions did not prevent a loss of activity. Vnfractionated supernatant activity was stable for up to 3 weeks at 4°C.
Electrophoretic mobility on native PACE.-Fractions frq~ molecular sieving containing aMCCT activity, as inaicated by the bars in text-figure 1, were pooled, concentrated 20 times and run on 7% native polyacrylamide tube gels. Gel slices were eluted with RPMI-3%, and eluates were then assayed on L-929 and HeLa cells in tube cultures. The data for these target cells are shown in text-figure 3. One peak of lytic activity was found on both the L-929 and HeLa targets. The R f values ranged from 0.15 to 0.30 with the major peak at an R f of 0.24-0.28 on both the L-929 and HeLa cells.
Effects of protease inhibitors on MCCT activity.-The reversible inhibitors tested were SBTI, TAME, and ALME; the irreversible inhibitors used were TLCK, Samples of 150 ILl were applied to 0.5X8-cm tube gels consisting of a I-cm 3% acrylamide stacking gel in 50 mM Tris-glycine, pH 9.0, and a 7% aery lam ide separation gel and electrophoresed as explained in "Materials and Methods." One-millimeter gel slices were incubated in RPMI-3% at 4°C for 12 hr to recover lytic activity. Samples of 200 ILl were tested for lytic activity on both L-929 (e---e) and HeLa cells (o---{)) in tube assays. Toxic activity of each sample is expressed as percent viability.
TPCK, and PMSF. The results of a single experiment are presented in table 6. Tests with the reversible inhibitors showed that IOmM TAME quite effectively blocked lytic activity. In contrast, ALME, which has a lysyl group in place of the arginyl group in TAME, did not block MCCT activity. BTl, which inhibits trypsin and trypsin-like proteases, showed an intermediate level of inhibition. Since TAME was incubated with aMCCT and target cells, the possibility existed that TAME could block an L-cell membrane-associated protease that was required for MCCT action. Therefore, aMCCT was incubated with the irreversible inhibitors TLCK, TPCK, and PMSF for I hour before addition to the L-cells. Samples were then dialyzed for 10-12 hours against PBS to remove unbound inhibitor. As the data in table 6 show, treatment with TLCK readily blocked aMCCT activity. This finding is especially interesting in light of the results with ALME, since both TLCK and ALME contain lysyl groups. Identical experiments conducted with TPCK as the inhibitor showed only minimal inhibition of aMCCT activity. Finally, when PMSF was employed as the inhibitor, we did not detect any decrease in the lytic effectiveness of aMCCT. In additional experiments we found that these levels of inhibitors had no effect on target cell viability. Effects of active oxygen scavengers on aMCCT activity,-Different levels of catalase activity were coincubated with aMCCT and target L-cells. The results of a single experiment are shown in table 7. In multiple experiments, however, we found that catalase at a concentration of 4,000 enzyme Vlml inhibited 75% of the aMCCT activity. The enzyme at this level had no detectable effect on L-cells. As a control, the enzyme preparation was dialyzed against 500 volumes of PBS for 24 hours; this preparation was equally effective in inhibiting aMCCT lysis (data not shown). As a further control, catalase was heated to 90°C for 10 minutes before addition to aMCCT. This treatment destroyed all enzymatic activity and removed the inhibitory effect on aMCCT activity.
Hypochlorous acid (HOCI) is formed from hydrogen peroxide (H202) and chloride ion (CI-) by the enzyme myeloperoxidase and is scavenged by the amino acids alanine, serine, and valine (25) . As table 7 illustrates, these amino acids at a concentration of 30 mM did not block lytic activity successfully when incubated simultaneously with aMCCT on L-cells.
DISCUSSION
Monocytes-macrophages can be promoted to a tumoricidal state by an appropriate combination of in vivo andlor in vitro priming and triggering events (1-5, 24, 26) . Most studies have revealed that this state is characterized by a selective cytotoxic effect preferentially manifested on neoplastic-transformed targets compared to their normal counterparts (1) (2) (3) (4) (5) (24) (25) (26) (27) . The molecular basis for the target injury phase of the lytic mechanism is currently unresolved; however, numerous mechanisms have been proposed, some of which invoke the extracellular release of a cell-lytic mediator by the macrophage into the fluid phase (6-8, 17,22, 28-32) .
The lack of a large-scale source of these monokines has been a major impediment to the complete functional and biochemical characterization of some of the candidate mediators and to a definition of their possible role in the lytic mechanism. In the murine system, the identification of the P388D 1 macrophage line as a source of lymphocyte activating factor (LAF -interleukin I) has facilitated biochemical and functional studies of this important monokine (33) . Recently, promising models of human monocyte-mediated tumor-cell killing in vitro have been forthcoming on the basis of phorbol ester-induced differentiation of monocytoid cell lines (12) (13) (14) (15) (16) . Concomitant with differentiation, typical macrophage characteristics are acquired, such as a reduced replicative potential, increased adherence to substratum and phagocytic capacity, expression of Fe receptors for IgG, detectable staining for cell-surface esterase, and tumor cytolytic capacity. In this study, we have isolated and initially characterized a cell-lytic mediator or mediators from PMA-treated THP-I monocytic leukemia cells.
As a biologic assay for cell-lytic molecules, we have employed mitomycin-treated target cells. Drug treatment increases the sensitivity of most targets to lytic effects of the mediators. This increased sensitivity has been reported in numerous cell-lytic systems and may reflect perturbed repair mechanisms andlor cell cydelinked sensitivity of the targets to the mediators (34) (35) (36) (37) . A similar assay has recently been employed as a rapid, sensitive assay for human monocyte cytotoxicity (38) . Furthermore, the use of nondividing targets in our bioassay allows the discrimination between cytolytic and cytostatic effects of the mediators. In this regard, Gaffney and colleagues (39) have described growth inhibitory substances released by merzerein-treated THP-I cells. The major component described by them was in the 20,000-to 30,000-dalton range, and it is apparently distinct from the b Data presented are from a representative experiment. 'These studies were conducted with 18.8 U/ml cxMCCT. dCatalase at 4,000 U/ml subjected to 90°C for 10 min before assay with cxMCCT. All enzymatic activity was destroyed by this process.
eThese studies were conducted with 3.5 U/ml cxMCCT. (40) have initially characterized cytostatic factors termed CstF I and CstF II, of molecular weights 55,000 and 40,000, respectively, obtained from cultured peripheral blood monocytes. On the basis of molecular weight, these factors appear to be distinct from those released by the THP-I cell line; however, given the high level of protease activity associated with the culture conditions used for the elicitation of CstF I and CstF II, one could not exclude their derivation from a higher molecular weight precursor. Furthermore, although Nissen-Meyer and Hammerstrom (40) did not detect cytolytic activity, only cytostatic activity, they employed the K562 erythroleukemia target in their assays. In our study, this target was highly resistant to lysis by activated \. THP-I supernatant compared to the L-929 target cell' (table 5) . This raises the possibility that their CstF I and CstF II would be lytically active in a bioassay that uses a more sensi ti ve target.
Matthews (6) has used a bioassay for cytolysis similar to that iri our study in the isolation and characterization of an antitumor cytotoxin from cultured human peripheral blood monocytes. The toxin has a molecular weight of 34,000 by molecular sieving and 140,000 by gradient PAGE. In standard PAGE, this toxin appears to have mobility similar to that of aMCCT. It is noteworthy that the K562 target is substantially less susceptible to lysis by the toxin than the actinomycin-D-treated L-929 cell; this finding is similar to our results.
Recently, Sone et al. (8) have reported the release of a cytolytic factor(s) from human alveolar macrophages. Although only initially characterized, their factor(s) could not be inhibited in lysis of the A375 melanoma by TAME or SBTI, which were effective in blocking the aMCCT-mediated lysis of L-929 targets (table 6) .
We have determined in our laboratory that human peripheral blood monocytes, isolated from plateletpheresis residues by Ficoll-Hypaque sedimentation and counterflow elutriation, can be induced to release celllytic molecules active in the L-929 bioassay (Klostergaard J: In preparation). We have initially characterized these molecules and found two distinct molecular weight forms with biologic activity: The larger is approximately 100,000-140,000 daltons and represents approximately 20% of the total activity; the smaller is about 65,000 daltons and is the predominant form. The sizes agree very closely with those reported here for aMCCT and j3MCCT, although the proportions are nearly inverted. Further characterization of these toxins from peripheral blood monocytes and comparison to the THP-l-derived toxins are under way.
Williams et al. (41) have reported that human B-cell lines release a factor that is active in the in vivo assay for tumor necrosis factor. Although these investigators have tentatively defined this as the human counterpart to jNCI, VOL. 74. NO. I. JANUARY 1985 tumor necrosis factor, we believe there is a strong likelihood that this factor is human a-class lymphotoxin, a-LT, on the basis of a number of characteristics including the molecular weight, the B-cell origin, and the augmentation in production with PMA (23, (41) (42) (43) . It is noteworthy that in our studies a highly specific anti-a-LT antiserum did not block aMCCT activity (data not shown). We propose that a-L T may well be active in the tumor necrosis factor in assay, but is distinct from monocyte-macrophage-derived cell toxins, some of which may be the more appropriate human counterparts to tumor necrosis factor. This hypothesis should be testable in the near future.
Finally, it is an intriguing possibility that aMCCT can mediate target cell lysis by both protease-dependent and oxidative mechanisms. These mechanisms have been proposed by a number of investigators as operative in monocyte-macrophage-mediated cell lysis (22, 24, 28, 29, (44) (45) (46) (47) . Indeed, in the murine system, Adams et al. (47) have shown that a macrophage-derived cytolytic protease and hydrogen peroxide may act synergistically in mediating target cell destruction. In the current studies, although any proposed model would have significant untested aspects to it, we can certainly eliminate the trivial possibility that H 2 0 2 is present in the 120,QOOdalton molecular sieving fractions. Furthermore, since PMA is only added during the initial 18-hour phase during which the THP-l cells become adherent and activated, and thereafter PMA-free media are replaced for the 48-hour release period, any residual PMA is most likely present at very low levels. This PMA could only arise by release from pretreated THP-I cells and must not be degraded by esterases during the subsequent culture. Thus after the serum-free supernatants are concentrated and subjected to molecular sieving, we expect any PMA to be below the threshold for most PMA-inducible events. Therefore, in the absence of direct quantitation of residual PMA levels, we tentatively exclude the role of PMA in eliciting peroxide from the target cells on which aMCCT activity is expressed. Further resolution of this mechanism, for example, to determine if aMCCT induces H 2 0 2 production by the target cell subsequent to binding, will be possible when this mediator can be sufficiently purified.
In this context, this report is an initial phase of our studies of models for human monocyte-macrophage cytotoxicity. To some extent the THP-l cell line satisfies the necessary criteria for such models and will provide sufficient sources for isolation, purification, characterization, and, if justified, gene cloning of molecular mediators of tumoricidal mechanisms.
